@article{2c87a22771e54f75841ce85508ff6a27,
title = "The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris",
abstract = "The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).",
keywords = "Candida auris, Caspofungin, Fluconazole, In vitro susceptibility, Invasive candidiasis, Murine model, T-2307",
author = "Wiederhold, {Nathan P.} and Najvar, {Laura K.} and Rosie Jaramillo and Marcos Olivo and Hoja Patterson and April Connell and Yoshiko Fukuda and Junichi Mitsuyama and Gabriel Catano and Patterson, {Thomas F.}",
note = "Funding Information: This project utilized preclinical services funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Department of Health and Human Services under contracts no. HHS272201100018I and HHSN272201700039I - Task Orders A28 and A01, respectively, to the University of Texas Health Science Center at San Antonio. Publisher Copyright: Copyright {\textcopyright} 2020 American Society for Microbiology. All Rights Reserved.",
year = "2020",
doi = "10.1128/AAC.02198-19",
language = "English (US)",
volume = "64",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",
}